Morabito Christopher's most recent trade in Astria Therapeutics Inc was a trade of 262,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 01 Apr 2024 | 10,000 | 10,000 (0%) | 0% | 3.9 | 38,700 | Common Stock |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.59 per share. | 01 Apr 2024 | 10,000 | 0 (0%) | 0% | 13.6 | 135,939 | Common Stock |
| Astria Therapeutics Inc | Morabito Christopher | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 9,200 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 26 Jan 2024 | 9,200 | 9,200 (0%) | 0% | 3.9 | 35,604 | Common Stock |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.15 per share. | 26 Jan 2024 | 9,200 | 0 (0%) | 0% | 11.1 | 102,552 | Common Stock |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.02 per share. | 26 Jan 2024 | 800 | 0 (0%) | 0% | 11.0 | 8,812 | Common Stock |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 800 | 99,200 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Morabito Christopher | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 26 Jan 2024 | 800 | 800 (0%) | 0% | 3.9 | 3,096 | Common Stock |
| Astria Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 59,744 | 59,744 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 9.16 per share. | 28 Jun 2021 | 1,100 | 1,100 (0%) | 0% | 9.2 | 10,076 | Common Stock |
| Fulcrum Therapeutics Inc | Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 163,000 | 163,000 | - | - | Stock Option (right to buy) |